Health8/14/2025•The Guardian

Eli Lilly ramps up UK price of weight loss jab Mounjaro after Trump demands

Eli Lilly ramps up UK price of weight loss jab Mounjaro after Trump demands

Eli Lilly, a US pharmaceutical company, is increasing the UK price of its weight loss medication Mounjaro by up to 170%. This comes after former US President Donald Trump put pressure on the pharmaceutical industry to make drugs more affordable for Americans. The price of a month's supply of the highest dose of Mounjaro will rise from £122 to £330 in the UK starting from September. Eli Lilly has attributed this price hike to Trump's demands for the industry to make drugs more accessible and cheaper for US consumers, even if it means raising prices in other markets like the UK. The article highlights the ongoing tension between the pharmaceutical industry's pricing practices and the efforts by governments, like the US under Trump, to make essential medications more affordable for their citizens.

Source: For the complete article, please visit the original source link below.

Related Articles

'That nagging feeling of dread': Is 'hang-xiety' a real thing?
🏥 Health12h ago•1 min read

'That nagging feeling of dread': Is 'hang-xiety' a real thing?

Cancer patient hit with £680 in parking charges
🏥 Health18h ago•1 min read

Cancer patient hit with £680 in parking charges

Family of woman who died after 'misread' smear test join calls for inquiry
🏥 Health18h ago•1 min read

Family of woman who died after 'misread' smear test join calls for inquiry

Proportion of people in Great Britain vaping who never smoked doubles in four years
🏥 Health20h ago•1 min read

Proportion of people in Great Britain vaping who never smoked doubles in four years

Reform MP raises concerns about second homes – then buys one for £800,000
🏥 Health21h ago•1 min read

Reform MP raises concerns about second homes – then buys one for £800,000

What do we know about death of anti-plague institute worker in Russia and is there a wider risk?
🏥 Health21h ago•1 min read

What do we know about death of anti-plague institute worker in Russia and is there a wider risk?